All In Biotech

NDA 211911 · Abbvie

Durysta

Bimatoprost · Ophthalmic · Prostaglandin Analog

Last checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Mar 4, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

39 Phase 3, 7 recruiting

FAERS reports

2,818

1,650 serious, 129 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2024.

DURYSTA ® (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). DURYSTA is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). ( 1 )

Mechanism: Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DURYSTA · BIMATOPROST 10MCG · IMPLANT, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bimatoprost" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective268
  • intraocular pressure increased113
  • ocular hyperaemia108
  • no adverse event107
  • eye irritation93
  • eye pain92
  • nausea80
  • dyspnoea78
  • vision blurred73
  • diarrhoea71
  • fatigue71
  • headache71

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
20054
20068
200712
200821
200922
201023
201136
201221
201351
201465
201582
2016119
2017207
2018180
2019198
2020237
2021299
2022232
2023299
2024238
2025238
2026216

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Durysta (Bimatoprost)

2024 spending

$1.3M

Beneficiaries

360

383 claims

Per beneficiary

$3,706

$1,979.34 per unit

View as table
YearSpending
2020$42,016
2021$217,275
2022$697,834
2023$965,229
2024$1,334,075

Part B: Durysta (Bimatoprost) · HCPCS J7351

2024 spending

$20.7M

Beneficiaries

6,292

10,009 claims

Per beneficiary

$3,290

2024 ASP limit $207.66 per unit

View as table
YearSpending
2020$4,870,998
2021$21,888,390
2022$21,215,843
2023$21,795,947
2024$20,702,805

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 248 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.